RecruitingPhase 2Phase 3NCT06506422
Empagliflozin Reversal of Arterial StiffnEss in Aging
SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Sponsor
University of Missouri-Columbia
Enrollment
80 participants
Start Date
Aug 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
Eligibility
Min Age: 60 YearsMax Age: 80 Years
Inclusion Criteria4
- Able to provide consent
- to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
- Stable anti-hypertensive medication regimen (if in use) for at least 90 days
- Evidence of arterial stiffening (defined as carotid-femoral PWV >/= 8 m/s) at the time of screening visit.
Exclusion Criteria17
- Diabetes
- BMI>/= 45kg/m2
- Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
- Estimated glomerular filtration rate GFR < 29 mL/min
- Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
- Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
- Use of hormone replacement therapy
- Body weight change ≥10% within the last 6 months
- Uncontrolled hypertension during screening visit (>180/110 mmHg)
- Symptomatic hypotension and/or a SBP <100 mmHg
- History of ketoacidosis
- High fall risk per assessment of study physician and/or safety officer at the time of screening (results must be abnormal for both fall risk assessments and orthostatic blood pressure measurements)
- Anticipated need of prolonged fasting
- History of recurrent UTIs or mycotic genital infections
- Following a low-carbohydrate diet (<20 grams/day)
- Participation in regular exercise > 3 days/week per week at a moderate or vigorous intensity
- Known sensitivity to nitrate medications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGEmpagliflozin 10 MG
10mg Empagliflozin daily for 12 weeks
DRUGPlacebo
10mg Placebo daily for 12 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06506422
Related Trials
Prebiotic Effects of California Grapes on Gut Health and Cardiometabolic Health in Overweight Men and Women
NCT065449541 location
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
NCT070990531 location
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
NCT062396881 location
Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG
NCT065014951 location
Arterial Stiffness and Blood Pressure
NCT064957103 locations